[go: up one dir, main page]

ATE437873T1 - 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten - Google Patents

4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Info

Publication number
ATE437873T1
ATE437873T1 AT06850430T AT06850430T ATE437873T1 AT E437873 T1 ATE437873 T1 AT E437873T1 AT 06850430 T AT06850430 T AT 06850430T AT 06850430 T AT06850430 T AT 06850430T AT E437873 T1 ATE437873 T1 AT E437873T1
Authority
AT
Austria
Prior art keywords
ylü
benzoäbüthiophen
pyrimidine
cancer
treatment
Prior art date
Application number
AT06850430T
Other languages
English (en)
Inventor
Karl Dahnke
Ho-Shen Lin
Chuan Shih
Q Wang
Bo Zhang
Michael Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE437873T1 publication Critical patent/ATE437873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06850430T 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten ATE437873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
ATE437873T1 true ATE437873T1 (de) 2009-08-15

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850430T ATE437873T1 (de) 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Country Status (27)

Country Link
US (1) US7547691B2 (de)
EP (1) EP1989200B1 (de)
JP (1) JP2009516697A (de)
KR (1) KR100990771B1 (de)
CN (1) CN101309918B (de)
AR (1) AR057911A1 (de)
AT (1) ATE437873T1 (de)
AU (1) AU2006337626B2 (de)
BR (1) BRPI0618245A2 (de)
CA (1) CA2629336A1 (de)
CR (1) CR9947A (de)
DE (1) DE602006008187D1 (de)
DK (1) DK1989200T3 (de)
EA (1) EA014426B1 (de)
EC (1) ECSP088456A (de)
ES (1) ES2329085T3 (de)
IL (1) IL190489A0 (de)
MA (1) MA30053B1 (de)
NO (1) NO20082594L (de)
PE (1) PE20070833A1 (de)
PL (1) PL1989200T3 (de)
PT (1) PT1989200E (de)
SI (1) SI1989200T1 (de)
TN (1) TNSN08227A1 (de)
TW (1) TW200800201A (de)
WO (1) WO2007092095A2 (de)
ZA (1) ZA200803940B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101460483B (zh) 2006-03-31 2013-05-08 詹森药业有限公司 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪
EP2044061A2 (de) * 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophen-hemmer der rho-kinase
BRPI0720607A2 (pt) * 2006-12-21 2014-04-08 Lilly Co Eli Compostos de imidazolidinonil aminopirimidina
EP2125793B1 (de) 2006-12-21 2010-09-01 Eli Lilly & Company Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
CL2008001322A1 (es) 2007-05-16 2009-05-22 Lilly Co Eli Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
EP2155734A2 (de) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl-aminopyrimidin-verbindungen
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2924035A1 (de) 2008-06-30 2015-09-30 Janssen Pharmaceutica NV Substituierte pyrimidinderivate
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
MX2012012502A (es) 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
WO2013058824A1 (en) 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物およびそれらの使用方法
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573970A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalin-1-yl)chinazolin-2-yl)azetidin-1-yl)prop-2-en-1-on-derivate und ähnliche verbindungen wie kras g12c-inhibitoren zur behandlung von krebs
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018218070A2 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
AU2018312559B2 (en) 2017-08-02 2022-06-02 Pgi Drug Discovery Llc Isochroman compounds and uses thereof
WO2020028706A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法

Also Published As

Publication number Publication date
CN101309918B (zh) 2010-12-29
BRPI0618245A2 (pt) 2011-08-23
EP1989200B1 (de) 2009-07-29
KR100990771B1 (ko) 2010-10-29
JP2009516697A (ja) 2009-04-23
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626B2 (en) 2012-03-22
AU2006337626A8 (en) 2008-06-19
EA014426B1 (ru) 2010-12-30
KR20080059451A (ko) 2008-06-27
TW200800201A (en) 2008-01-01
US7547691B2 (en) 2009-06-16
EP1989200A2 (de) 2008-11-12
ECSP088456A (es) 2008-06-30
DE602006008187D1 (de) 2009-09-10
PL1989200T3 (pl) 2009-12-31
WO2007092095A2 (en) 2007-08-16
WO2007092095A3 (en) 2007-11-08
EA200801362A1 (ru) 2009-02-27
ES2329085T3 (es) 2009-11-20
PE20070833A1 (es) 2007-08-27
CN101309918A (zh) 2008-11-19
PT1989200E (pt) 2009-10-12
IL190489A0 (en) 2008-11-03
SI1989200T1 (sl) 2009-12-31
MA30053B1 (fr) 2008-12-01
AR057911A1 (es) 2007-12-26
ZA200803940B (en) 2009-09-30
CR9947A (es) 2008-11-28
US20080306082A1 (en) 2008-12-11
NO20082594L (no) 2008-06-10
DK1989200T3 (da) 2009-11-09
TNSN08227A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
ATE437873T1 (de) 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin- derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten
DE602005014621D1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
NO20092658L (no) New compounds
DE602005007623D1 (de) Als cdk2- und angiogenese-inhibitoren und für die behandlung von brust-, kolon-, lungen- und prostatakrebs geeignete disubstituierte pyrazolobenzodiazepine
ATE458732T1 (de) Verwendung von 4-imidazol-derivaten für zns- erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NO20081539L (no) Middel for behandling av betennelsestarmsykdom
ATE542804T1 (de) 5-phenyl-pentansäurederivate als matrixmetalloproteinase-inhibitoren zur behandlung von asthma und anderen erkrankungen
ATE443991T1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
DE602006006950D1 (de) Zusammensetzungen, Verwendungen und Kit für die Behandlung von Dermatitis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1989200

Country of ref document: EP